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Raising the level of high-density lipoprotein (HDL) cholesterol has
been proposed as a potential therapeutic strategy to reduce car-
diovascular risk, largely based on the epidemiological studies
showing that low HDL cholesterol levels are associated with an
increased risk of coronary disease and cardiovascular events.1,2
This has been supported by experimental as well as translational
studies, which have demonstrated the anti-atherogenic properties
of HDL.3 This led to the perception of HDL cholesterol as the
‘good cholesterol’. Notably, in the Treating to New Targets
study, low HDL cholesterol levels remained a marker of increased
cardiovascular risk even in coronary patients with low LDL choles-
terol levels (,70 mg/dL) on statin therapy.2
Although initial studies proposed reverse macrophage choles-
terol transport by HDL as the main anti-atherogenic mechan-
ism,4 more recent studies highlighted endothelial-protective
properties of HDL, including the stimulation of endothelial
nitric oxide (NO) production, as well as anti-inflammatory, anti-
apoptotic, and anti-thrombotic effects.5,6 Importantly, however,
these studies have used HDL isolated from healthy subjects
or reconstituted HDL which differ in several ways from the
HDL obtained from patients with coronary disease, as discussed
below.
Inhibition of cholesteryl ester transfer protein (CETP) offers an
unprecedented opportunity to profoundly increase HDL choles-
terol plasma levels.7 This has resulted in several large-scale
programmes to explore the potential of CETP as a novel thera-
peutic target for cardiovascular prevention. The large randomized
ILLUMINATE trial examined the effects of the CETP inhibitor tor-
cetrapib on clinical outcomes in 15 067 patients at high cardiovas-
cular risk. In spite of a marked increase in plasma HDL cholesterol
levels of 72.1%, the trial had to be stopped due to increased
mortality and morbidity in the treatment group.8 In subsequent
mechanistic studies, the adverse effects of torcetrapib were attribu-
ted to off-target toxicity, in particular increased production of aldos-
terone as well as an increased production of endothelin and
reduced expression of endothelial nitric oxide synthase in the
vessel wall.9 These off-target effects of torcetrapib were held re-
sponsible for the observed increase in the arterial blood pressure
with this agent.8 Two post hoc analyses, the first in ILLUMINATE
and the second in ILLUSTRATE, the coronary IVUS study with tor-
cetrapib, indicated that those participants with the highest increase
in HDL cholesterol or achieved on-treatment HDL cholesterol
levels did show cardiovascular benefit. This raised hopes that
other CETP inhibitors without the off-target toxicity of torcetrapib
would lead to the prevention of recurrent events.8,10,11
The dal-HEART programme by Roche was a carefully designed
clinical development programme of another CETP inhibitor, dalce-
trapib, that, to the surprise of many, was stopped on Saturday, 5 May
2012. The interim analysis of the large phase-3 dal-OUTCOMES
trial, involving .15 600 patients with recent acute coronary syn-
drome, had revealed a lack of efficacy of the compound in reducing
cardiovascular events.12 This clinical trial programme was the first
development programme of a CETP inhibitor after the torcetrapib
failure. With this experience in mind, two safety studies, the
dal-VESSEL and the dal-PLAQUE studies, designed to exclude
adverse vascular effects of the compound, were part of the early de-
velopment programme.13,14 Whereas both studies did not reveal
adverse vascular effects of dalcetrapib therapy neither on endothe-
lial function as assessed by flow-mediated dilation nor on vascular
structure as examined by carotid MRI, there was also not a convin-
cing signal that the compound would exert protective effects on
these parameters.13,14
The opinions expressed in this article are not necessarily those of the editors of the European Heart Journal or the European Society of Cardiology.
* Corresponding author. Tel: +41 44 255 2121, Fax: +41 44 255 4251, Email: karlue@usz.uzh.ch
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2012. For permissions please email: journals.permissions@oup.com
European Heart Journal (2012) 33, 1712–1715
doi:10.1093/eurheartj/ehs182
Indeed, inspite of a marked increase in HDL cholesterol plasma
levels by 30% and a lack of effect on blood pressure, endothelial
function was not improved (as had been the case with reconsti-
tuted HDL).13,15 Similarly, despite a suggestion of potential
benefit, plaque size and inflammation (as assessed by positron
emission tomography using fluoro-deoxyglucose as tracer) were
not largely affected by the drug.14 Unfortunately, these findings
had received little attention, although they now appear in strong
agreement with the neutral outcome of the phase-3 clinical trial.
Another more potent CETP inhibitor, anacetrapib, is currently
developed by Merck and is being tested in a large phase 3 clinical
programme (see ClinicalTrials.gov Identifier: NCT01252953) after
the long-term safety study DEFINE revealed encouraging results on
blood pressure and lipids.16 Furthermore, Eli Lilly’s evacetrapib has
also entered a clinical trial programme.17 While dalcetrapib only
increased HDL cholesterol relatively modestly, both anacetrapib
and evacetrapib also markedly lower LDL cholesterol, small
dense LDL, lipoprotein (a), non-HDL cholesterol, and apolipopro-
tein B, even on top of potent statin therapy (Table 1). Moreover, a
very recent and large Mendelian randomization study has con-
firmed that lower CETP activity, when associated with both
lower LDL and higher HDL, is associated with cardiovascular
benefit.18 Similarly, in the Copenhagen City Heart Study CETP
gene variants associated with lower CETP activity are associated
with a reduced cardiovascular event rate (Anne Tybjaerg-
Hansen, personal communication).
The interpretation and prediction of the impact of CETP inhibi-
tions is complicated by the growing awareness that the effects of
HDL may vary in different clinical settings. For example, the
effects of HDL on macrophage cholesterol efflux and in particular
the endothelial effects of HDL are altered in patients with
coronary disease or diabetes, a phenomenon referred to as
‘HDL dysfunction’.3 Indeed, Khera et al. found that the cholesterol
efflux capacity of apoB-depleted serum (as a measure of the cap-
acity of HDL to accept cholesterol from macrophages) was in-
versely related to carotid intima-media thickness and the
likelihood of angiographic coronary artery disease independent
of the HDL cholesterol plasma levels.19 We have observed that
the capacity of HDL to stimulate endothelial NO production and
endothelial repair is substantially reduced in patients with coronary
artery disease or diabetes mellitus.20,21 Of note, HDL, isolated
from healthy subjects, substantially stimulated endothelial cell
NO production and accelerated endothelial repair in vivo,
whereas no such or even opposite effects were observed when
HDL was isolated from patients with coronary disease or dia-
betes.20,21 The underlying mechanisms need to be further
defined, but likely include increased lipid oxidation of HDL due
to a reduced HDL-associated paraoxonase-1 activity, an enzyme
that protects HDL from lipid oxidation, as well as modifications
of the protein moiety. High-density lipoprotein cholesterol is a
highly complex lipoprotein that can scavenge .70 proteins, as
identified by the proteomics analysis,22 and may contain .1000
different lipid species with each of them being modifiable. The vas-
cular effects of HDL are not necessarily predictable by simply
measuring its cholesterol concentration, since cholesterol is only
a non-functional cargo of this lipoprotein and hence a surrogate
marker reflecting the size and number of HDL particles. These
observations raise the possibility that the vascular effects of
on-treatment HDL may be an important determinant of the
overall cardiovascular benefits of an HDL-raising intervention.
Indeed, in certain clinical settings, an increase of dysfunctional
HDL particles could also be detrimental. Hence, both the
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Table 1 Properties and effects of different cholesteryl ester transfer protein inhibitors observed in clinical trials on
plasma lipid levels and blood pressure
Anacetrapib Dalcetrapib Evacetrapib Torcetrapib
Lipids (per cent change, %)
HDL-C +130–140 +30–40 +70–90 +70–80
LDL-C 230–40 20–7 210–40 220–30
Increase in blood pressure
Systolic No effect No effect No effect 3–6 mmHg
Molecular weight




on-treatment vascular effects of HDL as well as the underlying mo-
lecular mechanism leading to increased HDL cholesterol levels are
likely important determinants of the overall vascular effects of an
HDL-cholesterol-raising therapeutic intervention. Thus, targeting
HDL by CETP inhibition remains a ‘rocky road’. It appears that
we need to learn more about the biology of HDL and its relation
to atherosclerotic vascular disease. Notably easy-to-measure bio-
markers reflecting HDL functionality better than HDL cholesterol
or apoA-I levels are urgently needed. In this regard, post hoc ana-
lyses of Dal-OUTCOME and its biobank may turn out to be a
highly valuable resource towards better understanding of the dal-
cetrapib failure. The extensive dal-HEART programme included
early safety studies with surrogate measures as an endpoint to
detect potential adverse effects of dalcetrapib early on. It is note-
worthy that the dal-VESSEL study neither showed evidence of
adverse vascular effects of dalcetrapib, nor a signal for a beneficial
effect on vascular function.13 The dal-PALQUE study showed
some rather weak effects on the carotid wall.
Atherosclerosis progresses for many years before clinical events
and involves dysfunctional vascular biology characterized by inflam-
mation and endothelial dysfunction. In hindsight, the lack of convin-
cing positive signals from the two studies of function and structure
might have been given more weight. Perhaps the lack of a clear
positive signal in such studies should also give reason for
concern about the efficacy of a particular target in cardiovascular
prevention in the future as well. Further development of athero-
sclerotic plaque imaging may also be valuable in this respect.
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